Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership TeamBusiness Wire • 03/26/24
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ProgressBusiness Wire • 02/26/24
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)Business Wire • 02/13/24
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/02/24
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?Zacks Investment Research • 11/09/23
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent ProgressBusiness Wire • 11/06/23
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)Business Wire • 10/19/23
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)Business Wire • 10/02/23
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines ConferenceBusiness Wire • 09/26/23
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket PharmaceuticalsThe Motley Fool • 09/23/23
Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread CarefullyThe Motley Fool • 09/18/23
Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead?Seeking Alpha • 09/14/23
Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential 'Value Driver.Barrons • 09/13/23